Skip to main
ADUS
ADUS logo

Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare (ADUS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Addus HomeCare Corp has demonstrated robust organic revenue growth across its segments, particularly with a notable increase of +12.3% year-over-year in 2023. This growth trajectory is further supported by projected steady advancements in the Hospice segment, which is anticipated to achieve revenue growth of +5% to +7%. Additionally, the finalized FY2026 Medicare Hospice rate increase of +2.6%, effective 10/1/25, is expected to enhance financial stability and operational efficiency, contributing positively to the company’s future performance.

Bears say

Addus HomeCare's financial outlook appears negative due to ongoing same-store declines, driven by administrative bottlenecks related to Medicaid redeterminations, leading to higher patient discharges compared to new admissions. The company's reliance on Medicaid funding, which constituted approximately 97% of its segment revenues in 2025 year-to-date, raises concerns about future earnings stability given the uncertainties surrounding the One Big Beautiful Bill Act (OBBBA). Furthermore, despite steady operational execution and a favorable long-term demand backdrop, Addus HomeCare's stock performance has lagged relative to the broader post-acute care sector, indicating a potential disconnect between equity valuation and fundamental performance.

Addus HomeCare (ADUS) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Addus HomeCare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Addus HomeCare (ADUS) Forecast

Analysts have given Addus HomeCare (ADUS) a Buy based on their latest research and market trends.

According to 9 analysts, Addus HomeCare (ADUS) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Addus HomeCare (ADUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.